Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NICHOLAS PATRICK MCANDREW

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1093074106
CMS profile
906526
Location
LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$854.83

4 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $685.00 1
Food and Beverage $169.83 3

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $685.00 1
E.R. Squibb & Sons, L.L.C. $116.94 1
BeiGene USA, Inc. $52.89 2

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NICHOLAS PATRICK MCANDREW

NPI 1093074106 · CMS profile ID 906526

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1093074106?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NICHOLAS PATRICK MCANDREW, NPI 1093074106, CMS profile ID 906526. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1093074106?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). NICHOLAS PATRICK MCANDREW, NPI 1093074106, CMS profile ID 906526. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1093074106?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
NICHOLAS PATRICK MCANDREW, NPI 1093074106, CMS profile ID 906526, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1093074106?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

4 matching records · $854.83 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 4 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–4 of 4.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
BeiGene USA, Inc. $29.1212/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051196613 CMS
BeiGene USA, Inc. $23.7711/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051196611 CMS
E.R. Squibb & Sons, L.L.C. $116.9410/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016293335 CMS
AstraZeneca Pharmaceuticals LP $685.0003/16/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011434723 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,170.23 5
PY2020 $12,939.92 12
PY2021 $2,820.00 2
PY2022 $8,355.00 3
PY2023 $854.83 4
PY2024 $4,405.87 15
PY2025 $9,621.75 17

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $872.20 1
PY2025 Principal investigator $596,816.77 153
PY2024 Recipient $1,633.83 1
PY2024 Principal investigator $3,352,829.60 63
PY2023 Recipient $1,409.82 1
PY2023 Principal investigator $2,151,571.63 67
PY2022 Principal investigator $2,868,775.41 36
PY2021 Principal investigator $3,830,116.22 25
PY2020 Principal investigator $6,585,760.41 40
PY2019 Principal investigator $3,438,563.63 29

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

154 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $1,550.00 11/14/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A SINGLE ARM OPEN LABEL PHASE 2 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB DERUXTECAN IN SUBJECTS WITH PREVIOUSLY TREATED UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER No dispute reported 06/30/2026 1228738925
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,439.00 11/11/2025 Non-covered Recipient Entity
UCLA MEDICAL CENTER
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1190304611
Principal investigator 1 Daiichi Sankyo Inc. $16,349.00 11/07/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352696
Principal investigator 1 PFIZER INC. $14,065.00 11/07/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228738159
Principal investigator 1 Daiichi Sankyo Inc. $120.00 10/15/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352690
Principal investigator 1 Daiichi Sankyo Inc. $200.00 10/15/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352692
Principal investigator 1 Daiichi Sankyo Inc. $200.00 10/15/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352694
Principal investigator 1 Daiichi Sankyo Inc. $200.00 10/15/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352698
Principal investigator 1 PFIZER INC. $5,430.00 10/10/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A SINGLE ARM OPEN LABEL PHASE 2 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB DERUXTECAN IN SUBJECTS WITH PREVIOUSLY TREATED UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER No dispute reported 06/30/2026 1228749801
Principal investigator 1 PFIZER INC. $578.00 09/24/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228758841
Principal investigator 1 PFIZER INC. $14,445.00 09/10/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228770281
Principal investigator 1 PFIZER INC. $10,342.34 09/08/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A PHASE 1B TRIAL EVALUATING THE SAFETY OF RIBOCICLIB TUCATINIB AND TRASTUZUMAB IN PATIENTS WITH METASTATIC HER2 BREAST CANCER AND A MULTICENTER RANDOMIZED OPENLABEL PHASE 2 STUDY OF PREOPERATIVE TREATMENT WITH RIBOCICLIB TRASTUZUMAB TUCATINIB A No dispute reported 06/30/2026 1228759557
Principal investigator 1 PFIZER INC. $3,582.19 09/08/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A PHASE 1B TRIAL EVALUATING THE SAFETY OF RIBOCICLIB TUCATINIB AND TRASTUZUMAB IN PATIENTS WITH METASTATIC HER2 BREAST CANCER AND A MULTICENTER RANDOMIZED OPENLABEL PHASE 2 STUDY OF PREOPERATIVE TREATMENT WITH RIBOCICLIB TRASTUZUMAB TUCATINIB A No dispute reported 06/30/2026 1228769151
Principal investigator 1 PFIZER INC. $10,940.00 08/13/2025 Non-covered Recipient Entity
UCLA Medical Center
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228718101
Principal investigator 1 PFIZER INC. $5,470.00 08/12/2025 Non-covered Recipient Entity
UCLA Medical Center
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228717287
Principal investigator 1 PFIZER INC. $578.00 07/24/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228764637
Principal investigator 1 PFIZER INC. $11,968.00 07/11/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228773184
Principal investigator 1 Daiichi Sankyo Inc. $200.00 06/26/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352668
Principal investigator 1 Daiichi Sankyo Inc. $903.30 06/26/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352670
Principal investigator 1 Daiichi Sankyo Inc. $200.00 06/26/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352672
Principal investigator 1 Daiichi Sankyo Inc. $200.00 06/26/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352674
Principal investigator 1 Daiichi Sankyo Inc. $200.00 06/26/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352676
Principal investigator 1 Daiichi Sankyo Inc. $200.00 06/26/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352678
Principal investigator 1 Daiichi Sankyo Inc. $200.00 06/26/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352686
Principal investigator 1 PFIZER INC. $600.00 06/17/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A SINGLE ARM OPEN LABEL PHASE 2 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB DERUXTECAN IN SUBJECTS WITH PREVIOUSLY TREATED UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER No dispute reported 06/30/2026 1228774397
Principal investigator 1 PFIZER INC. $10,593.40 06/17/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228776564
Principal investigator 1 PFIZER INC. $289.00 06/17/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228777521
Principal investigator 1 PFIZER INC. $5,670.00 06/17/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228777666
Recipient Novartis Pharmaceuticals Corporation $872.20 05/13/2025 Covered Recipient Physician CLEE011O12301C No dispute reported 06/30/2026 1190291357
Principal investigator 1 Daiichi Sankyo Inc. $200.00 05/09/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352596
Principal investigator 1 Daiichi Sankyo Inc. $200.00 05/09/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352598
Principal investigator 1 Daiichi Sankyo Inc. $200.00 05/09/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352600
Principal investigator 1 Daiichi Sankyo Inc. $1,578.00 05/09/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352602
Principal investigator 1 Daiichi Sankyo Inc. $200.00 05/09/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352604
Principal investigator 1 Daiichi Sankyo Inc. $200.00 05/09/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352606
Principal investigator 1 Daiichi Sankyo Inc. $200.00 05/09/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352608
Principal investigator 1 Daiichi Sankyo Inc. $200.00 05/09/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352610
Principal investigator 1 Daiichi Sankyo Inc. $200.00 05/09/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352612
Principal investigator 1 Daiichi Sankyo Inc. $200.00 05/09/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352614
Principal investigator 1 Daiichi Sankyo Inc. $200.00 05/09/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352616
Principal investigator 1 Daiichi Sankyo Inc. $200.00 05/09/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352618
Principal investigator 1 Daiichi Sankyo Inc. $200.00 05/09/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352620
Principal investigator 1 Daiichi Sankyo Inc. $200.00 05/09/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352622
Principal investigator 1 Daiichi Sankyo Inc. $200.00 05/09/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352624
Principal investigator 1 Daiichi Sankyo Inc. $200.00 05/09/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352626
Principal investigator 1 Daiichi Sankyo Inc. $200.00 05/09/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352628
Principal investigator 1 Daiichi Sankyo Inc. $200.00 05/09/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352630
Principal investigator 1 Daiichi Sankyo Inc. $200.00 05/09/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352632
Principal investigator 1 Daiichi Sankyo Inc. $1,578.00 05/09/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352634
Principal investigator 1 Daiichi Sankyo Inc. $1,578.00 05/09/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352636
Principal investigator 1 Daiichi Sankyo Inc. $1,578.00 05/09/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352638
Principal investigator 1 Daiichi Sankyo Inc. $200.00 05/09/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352640
Principal investigator 1 Daiichi Sankyo Inc. $200.00 05/09/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352642
Principal investigator 1 Daiichi Sankyo Inc. $200.00 05/09/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352644
Principal investigator 1 Daiichi Sankyo Inc. $200.00 05/09/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352646
Principal investigator 1 Daiichi Sankyo Inc. $200.00 05/09/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352648
Principal investigator 1 Daiichi Sankyo Inc. $200.00 05/09/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352650
Principal investigator 1 Daiichi Sankyo Inc. $2,883.00 05/09/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352652
Principal investigator 1 Daiichi Sankyo Inc. $2,883.00 05/09/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352654
Principal investigator 1 Daiichi Sankyo Inc. $341.40 05/09/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352656
Principal investigator 1 Daiichi Sankyo Inc. $200.00 05/09/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352658
Principal investigator 1 Daiichi Sankyo Inc. $200.00 05/09/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352660
Principal investigator 1 Daiichi Sankyo Inc. $200.00 05/09/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352662
Principal investigator 1 Daiichi Sankyo Inc. $200.00 05/09/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352664
Principal investigator 1 Daiichi Sankyo Inc. $200.00 05/09/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352666
Principal investigator 1 Daiichi Sankyo Inc. $200.00 05/09/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352680
Principal investigator 1 Daiichi Sankyo Inc. $200.00 05/09/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352682
Principal investigator 1 Daiichi Sankyo Inc. $200.00 05/09/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352684
Principal investigator 1 Daiichi Sankyo Inc. $200.00 05/09/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352688
Principal investigator 1 PFIZER INC. $5,481.00 04/21/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228800282
Principal investigator 1 Daiichi Sankyo Inc. $1,260.00 04/16/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352700
Principal investigator 1 Daiichi Sankyo Inc. $7,182.00 04/16/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352702
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,017.10 04/16/2025 Non-covered Recipient Entity
UCLA HEALTH SANTA MONICA CANCER CARE
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1190303417
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,012.10 04/16/2025 Non-covered Recipient Entity
UCLA HEALTH PASADENA CANCER CARE
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1190303653
Principal investigator 1 Novartis Pharmaceuticals Corporation $563.94 04/16/2025 Non-covered Recipient Entity
UCLA MEDICAL CENTER
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1190304609
Principal investigator 1 Novartis Pharmaceuticals Corporation $548.10 04/16/2025 Non-covered Recipient Entity
UCLA HEALTH HEMATOLOGY ONCOLOGY
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1190304973
Principal investigator 1 Novartis Pharmaceuticals Corporation $548.10 04/16/2025 Non-covered Recipient Entity
UCLA BURBANK
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1190307175
Principal investigator 1 Novartis Pharmaceuticals Corporation $548.10 04/16/2025 Non-covered Recipient Entity
UCLA HEM ONCOLOGY LAGUNA HILLS
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1190308268
Principal investigator 1 Novartis Pharmaceuticals Corporation $548.10 04/16/2025 Non-covered Recipient Entity
UCLA WESTLAKE VILLAGE PRIMARY AND SPECIALTY CARE
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1190308494
Principal investigator 1 Novartis Pharmaceuticals Corporation $548.10 04/16/2025 Non-covered Recipient Entity
UCLA HEALTH HEMATOLOGY ONCOLOGY ENCINO
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1190308538
Principal investigator 1 PFIZER INC. $16,443.00 04/10/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A SINGLE ARM OPEN LABEL PHASE 2 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB DERUXTECAN IN SUBJECTS WITH PREVIOUSLY TREATED UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER No dispute reported 06/30/2026 1228780616
Principal investigator 1 PFIZER INC. $39,703.86 03/28/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A PHASE 1B TRIAL EVALUATING THE SAFETY OF RIBOCICLIB TUCATINIB AND TRASTUZUMAB IN PATIENTS WITH METASTATIC HER2 BREAST CANCER AND A MULTICENTER RANDOMIZED OPENLABEL PHASE 2 STUDY OF PREOPERATIVE TREATMENT WITH RIBOCICLIB TRASTUZUMAB TUCATINIB A No dispute reported 06/30/2026 1228796175
Principal investigator 1 PFIZER INC. $578.00 03/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228787827
Principal investigator 1 PFIZER INC. $10,999.17 03/19/2025 Non-covered Recipient Entity
UCLA Medical Center
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228755679
Principal investigator 1 PFIZER INC. $43,996.68 03/18/2025 Non-covered Recipient Entity
UCLA Medical Center
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228757874
Principal investigator 1 PFIZER INC. $14,445.00 03/13/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228794675
Principal investigator 1 PFIZER INC. $5,470.00 03/10/2025 Non-covered Recipient Entity
UCLA Medical Center
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228754968
Principal investigator 1 Novartis Pharmaceuticals Corporation $132,439.89 03/05/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A multicenter phase 1b trial evaluating the safety of Ribociclib, Tucatinib, and Trastuzumab in patients with metastatic HER2+ breast cancer and a multicenter, randomized, open label, phase 2 study of preoperative treatment with Ribicliclib, Trastuzumab No dispute reported 06/30/2026 1190293368
Principal investigator 1 Eli Lilly and Company $59,714.30 02/14/2025 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A STUDY OF LOXO-783 ADMINISTERED AS MONOTHERAPY AND IN COMBINATION WITH ANTICANCER THERAPIES FOR PATIENTS WITH ADVANCED BREAST CANCER AND OTHER SOLID TUMORS WITH A PIK3CA H1047R MUTATION No dispute reported 06/30/2026 1187874915
Principal investigator 1 PFIZER INC. $10,940.00 02/13/2025 Non-covered Recipient Entity
UCLA Medical Center
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228757300
Principal investigator 1 PFIZER INC. $17,746.00 02/03/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228797415
Principal investigator 1 Daiichi Sankyo Inc. $3,150.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352474
Principal investigator 1 Daiichi Sankyo Inc. $5,040.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352476
Principal investigator 1 Daiichi Sankyo Inc. $3,591.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352478
Principal investigator 1 Daiichi Sankyo Inc. $794.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352480
Principal investigator 1 Daiichi Sankyo Inc. $120.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352482
Principal investigator 1 Daiichi Sankyo Inc. $630.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1223352484
Principal investigator 1 Daiichi Sankyo Inc. $200.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352486
Principal investigator 1 Daiichi Sankyo Inc. $200.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352488
Principal investigator 1 Daiichi Sankyo Inc. $200.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352490
Principal investigator 1 Daiichi Sankyo Inc. $200.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352492
Principal investigator 1 Daiichi Sankyo Inc. $200.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352494
Principal investigator 1 Daiichi Sankyo Inc. $200.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352496
Principal investigator 1 Daiichi Sankyo Inc. $200.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352498
Principal investigator 1 Daiichi Sankyo Inc. $200.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352500
Principal investigator 1 Daiichi Sankyo Inc. $939.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352502
Principal investigator 1 Daiichi Sankyo Inc. $1,213.40 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352510
Principal investigator 1 Daiichi Sankyo Inc. $2,365.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352512
Principal investigator 1 Daiichi Sankyo Inc. $939.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352514
Principal investigator 1 Daiichi Sankyo Inc. $2,497.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352516
Principal investigator 1 Daiichi Sankyo Inc. $2,497.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352518
Principal investigator 1 Daiichi Sankyo Inc. $2,531.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352520
Principal investigator 1 Daiichi Sankyo Inc. $2,302.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352522
Principal investigator 1 Daiichi Sankyo Inc. $2,302.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352524
Principal investigator 1 Daiichi Sankyo Inc. $2,302.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352526
Principal investigator 1 Daiichi Sankyo Inc. $2,365.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352528
Principal investigator 1 Daiichi Sankyo Inc. $2,497.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352530
Principal investigator 1 Daiichi Sankyo Inc. $2,531.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352532
Principal investigator 1 Daiichi Sankyo Inc. $2,531.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352534
Principal investigator 1 Daiichi Sankyo Inc. $2,365.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352536
Principal investigator 1 Daiichi Sankyo Inc. $1,137.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352538
Principal investigator 1 Daiichi Sankyo Inc. $1,481.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352540
Principal investigator 1 Daiichi Sankyo Inc. $2,302.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352542
Principal investigator 1 Daiichi Sankyo Inc. $200.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352544
Principal investigator 1 Daiichi Sankyo Inc. $2,302.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352546
Principal investigator 1 Daiichi Sankyo Inc. $200.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352548
Principal investigator 1 Daiichi Sankyo Inc. $200.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352550
Principal investigator 1 Daiichi Sankyo Inc. $200.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352552
Principal investigator 1 Daiichi Sankyo Inc. $2,531.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352554
Principal investigator 1 Daiichi Sankyo Inc. $200.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352556
Principal investigator 1 Daiichi Sankyo Inc. $200.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352558
Principal investigator 1 Daiichi Sankyo Inc. $1,137.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352560
Principal investigator 1 Daiichi Sankyo Inc. $2,365.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352562
Principal investigator 1 Daiichi Sankyo Inc. $939.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352564
Principal investigator 1 Daiichi Sankyo Inc. $200.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352566
Principal investigator 1 Daiichi Sankyo Inc. $3,721.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352568
Principal investigator 1 Daiichi Sankyo Inc. $2,848.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352570
Principal investigator 1 Daiichi Sankyo Inc. $200.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352572
Principal investigator 1 Daiichi Sankyo Inc. $939.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352574
Principal investigator 1 Daiichi Sankyo Inc. $200.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352576
Principal investigator 1 Daiichi Sankyo Inc. $200.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352578
Principal investigator 1 Daiichi Sankyo Inc. $2,302.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352580
Principal investigator 1 Daiichi Sankyo Inc. $200.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352582
Principal investigator 1 Daiichi Sankyo Inc. $2,594.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352584
Principal investigator 1 Daiichi Sankyo Inc. $2,365.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352586
Principal investigator 1 Daiichi Sankyo Inc. $200.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352588
Principal investigator 1 Daiichi Sankyo Inc. $200.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352590
Principal investigator 1 Daiichi Sankyo Inc. $200.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352592
Principal investigator 1 Daiichi Sankyo Inc. $2,848.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U302 No dispute reported 06/30/2026 1223352594
Principal investigator 1 PFIZER INC. $289.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228802036
Principal investigator 1 Novartis Pharmaceuticals Corporation $578.10 01/24/2025 Non-covered Recipient Entity
UCLA HEMATOLOGY ONCOLOGY BEV HILLS
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1190308546
Principal investigator 1 PFIZER INC. $1,000.00 01/21/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A SINGLE ARM OPEN LABEL PHASE 2 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB DERUXTECAN IN SUBJECTS WITH PREVIOUSLY TREATED UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER No dispute reported 06/30/2026 1228800412
Principal investigator 1 Novartis Pharmaceuticals Corporation $573.10 01/14/2025 Non-covered Recipient Entity
UCLA VALENCIA
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1190309784
Principal investigator 1 PFIZER INC. $200.00 01/06/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A SINGLE ARM OPEN LABEL PHASE 2 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB DERUXTECAN IN SUBJECTS WITH PREVIOUSLY TREATED UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER No dispute reported 06/30/2026 1228800606